Innoviva, Inc. (INVA) |
|
14.89 0.13 (0.88%)
|
07-02 20:29 |
|
Open: |
14.72 |
Pre. Close: |
14.76 |
|
High:
|
14.98 |
Low:
|
14.61 |
|
Volume:
|
613,420 |
Market Cap:
|
1,038(M) |
|
|
|
|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
14.99 - 15.07 |
15.07 - 15.13 |
|
Low:
|
14.44 - 14.52 |
14.52 - 14.59 |
|
Close:
|
14.76 - 14.89 |
14.89 - 15.01 |
|
Technical analysis |
as of: 2022-07-01 4:22:55 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 18.3 One year: 21.37 |
| Support: |
Support1: 14.67 Support2: 14.06 |
| Resistance: |
Resistance1: 15.67 Resistance2: 18.3 |
| Pivot: |
14.76 |
| Moving Average: |
MA(5): 14.99 MA(20): 14.85 
MA(100): 17.25 MA(250): 16.6 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 60.3 %D(3): 62.6 |
| RSI: |
RSI(14): 46.6 |
| 52-week: |
High: 20.7 Low: 12.9 |
| Average Vol(K): |
3-Month: 966 (K) 10-Days: 1,053 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INVA ] has closed below upper band by 38.0%. Bollinger Bands are 63.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 01 Jul 2022
Ukrainian Forces Destroy Two Upgraded Russian Tanks, 35 Inva... - MENAFN.COM
Wed, 22 Jun 2022
Ukrainian Army Liberates 1026 Settlements From Russian Inva... - MENAFN.COM
Tue, 07 Jun 2022
Continuing To Avoid Innoviva Stock (NASDAQ:INVA) - Seeking Alpha
Fri, 03 Jun 2022
'F**king Incompetent:' Russian Soldiers Bash Vladimir Putin, Close Aides - Benzinga - Benzinga
Fri, 03 Jun 2022
After Hours Most Active for Jun 3, 2022 : MNDT, TSM, PM, QQQ, INVA, CERN, INTC, AAPL, ERJ, COTY, INFY, PLTR - Nasdaq
Mon, 23 May 2022
Innoviva to acquire Entasis Therapeutics for $2.20/share (NASDAQ:INVA) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
69 (M) |
| Shares Float |
57 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
107.2 (%) |
|
Shares Short
|
12,340 (K) |
|
Shares Short P.Month
|
11,830 (K) |
Stock Financials |
|
EPS
|
3.06 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.8 |
|
Profit Margin (%)
|
47.2 |
|
Operating Margin (%)
|
95 |
|
Return on Assets (ttm)
|
21.4 |
|
Return on Equity (ttm)
|
47.5 |
|
Qtrly Rev. Growth
|
5.3 |
|
Gross Profit (p.s.)
|
5.63 |
|
Sales Per Share
|
5.7 |
|
EBITDA (p.s.)
|
5.42 |
|
Qtrly Earnings Growth
|
-76.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
4.85 |
|
PEG Ratio
|
0.4 |
|
Price to Book value
|
2.56 |
|
Price to Sales
|
2.61 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2015-09-29 |
|
Ex-Dividend Date
|
2015-09-07 |
|
7 Binary Options
|
|
Your Ad Here
|
|
